Mary B Daly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5979913/publications.pdf Version: 2024-02-01



MADY R DALY

#	Article	IF	CITATIONS
1	Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. International Journal of Epidemiology, 2023, 52, 272-283.	0.9	1
2	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	0.8	90
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
4	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
5	OUP accepted manuscript. International Journal of Epidemiology, 2022, , .	0.9	0
6	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews, 2022, 104, 102337.	3.4	6
7	Investigating the impact of the COVID-19 pandemic on breast cancer clinicians' communication about sexual health. Supportive Care in Cancer, 2022, 30, 5801-5810.	1.0	4
8	Coping With Changes to Sex and Intimacy After a Diagnosis of Metastatic Breast Cancer: Results From a Qualitative Investigation With Patients and Partners. Frontiers in Psychology, 2022, 13, 864893.	1.1	4
9	Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). Cancer Prevention Research, 2022, 15, 185-191.	0.7	4
10	Comparing 5-Year and Lifetime Risks of Breast CancerÂusing the Prospective Family Study Cohort. Journal of the National Cancer Institute, 2021, 113, 785-791.	3.0	13
11	Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncology, 2021, 7, 585-592.	3.4	16
12	The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
13	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
14	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966.	2.0	11
15	Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention. JCO Precision Oncology, 2021, 5, 1387-1396.	1.5	23
16	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
17	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
18	Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , .	2.3	7

#	Article	IF	CITATIONS
19	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	1.6	2
20	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	1.4	1
21	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
22	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. Journal of the National Cancer Institute, 2020, 112, 418-422.	3.0	1
23	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. Cancer Research, 2020, 80, 116-125.	0.4	37
24	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
25	Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 681-685.	1.1	20
26	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
27	Navigating the Intersection between Genomic Research and Clinical Practice. Cancer Prevention Research, 2020, 13, 219-222.	0.7	4
28	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
29	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
30	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics in Medicine, 2020, 22, 1401-1406.	1.1	4
31	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
32	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
33	Evaluating a couple-based intervention addressing sexual concerns for breast cancer survivors: study protocol for a randomized controlled trial. Trials, 2020, 21, 173.	0.7	18
34	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
35	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	5.8	30
36	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	2.2	41

#	Article	IF	CITATIONS
37	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
38	Breast Cancer Chemoprevention—Can We Make a Case for Precision Medicine?. JAMA Oncology, 2019, 5, 1542.	3.4	2
39	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
40	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
41	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
42	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Research, 2019, 21, 52.	2.2	44
43	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
44	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
45	Association of Prepubertal and Adolescent Androgen Concentrations With Timing of Breast Development and Family History of Breast Cancer. JAMA Network Open, 2019, 2, e190083.	2.8	7
46	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International Journal of Cancer, 2019, 145, 370-379.	2.3	9
47	A brief intervention to enhance breast cancer clinicians' communication about sexual health: Feasibility, acceptability, and preliminary outcomes. Psycho-Oncology, 2019, 28, 872-879.	1.0	21
48	10-year performance of four models of breast cancer risk: a validation study. Lancet Oncology, The, 2019, 20, 504-517.	5.1	116
49	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Research, 2019, 21, 128.	2.2	27
50	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
51	Preferences for inâ€person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics, 2019, 95, 293-301.	1.0	16
52	Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Education and Counseling, 2019, 102, 436-442.	1.0	38
53	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>2</i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
54	Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk. Journal of the National Cancer Institute, 2019, 111, 331-334.	3.0	31

#	Article	IF	CITATIONS
55	Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian. Canadian Journal of Urology, 2019, 26, 29-30.	0.0	2
56	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute, 2018, 110, 985-993.	3.0	35
57	Breast cancer family history and allele-specific DNA methylation in the legacy girls study. Epigenetics, 2018, 13, 240-250.	1.3	10
58	Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer. Breast Cancer Research, 2018, 20, 33.	2.2	9
59	Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10
60	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	2.2	51
61	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
62	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
63	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genetics in Medicine, 2017, 19, 30-35.	1.1	53
64	Dietary isoflavone intake and allâ€cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer, 2017, 123, 2070-2079.	2.0	67
65	Multigene Panel Testing and Breast Cancer Risk. JAMA Oncology, 2017, 3, 1176.	3.4	8
66	Effective patient-provider communication about sexual concerns in breast cancer: a qualitative study. Supportive Care in Cancer, 2017, 25, 3199-3207.	1.0	63
67	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
68	LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. Breast Cancer Research, 2017, 19, 62.	2.2	36
69	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
70	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
71	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
72	The Protein Encoded by the CCDC170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine, 2017, 22, 28-43.	2.7	26

#	Article	IF	CITATIONS
73	Talking about women's sexual health after cancer: Why is it so hard to move the needle?. Cancer, 2017, 123, 4757-4763.	2.0	34
74	Non-invasive optical spectroscopic monitoring of breast development during puberty. Breast Cancer Research, 2017, 19, 12.	2.2	14
75	Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. Breast Cancer Research, 2017, 19, 69.	2.2	18
76	Patient-provider communication about sexual concerns in cancer: a systematic review. Journal of Cancer Survivorship, 2017, 11, 175-188.	1.5	123
77	Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precision Oncology, 2017, 1, 1-17.	1.5	27
78	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
79	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
80	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
81	Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With <i>BRCA1/2</i> or Breast Cancer History. Journal of Clinical Oncology, 2016, 34, 3409-3416.	0.8	16
82	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
83	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
84	Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Familial Cancer, 2016, 15, 697-706.	0.9	68
85	Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). International Journal of Epidemiology, 2016, 45, 683-692.	0.9	48
86	Family Communication of Genetic Risk: A Personalized Approach. Current Genetic Medicine Reports, 2016, 4, 35-40.	1.9	5
87	Comparison of Clinical, Maternal, and Self Pubertal Assessments: Implications for Health Studies. Pediatrics, 2016, 138, .	1.0	36
88	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
89	Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. Journal of Medical Internet Research, 2016, 18, e23.	2.1	79
90	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34

#	Article	IF	CITATIONS
91	Psychosocial Adjustment in School-age Girls With a Family History of Breast Cancer. Pediatrics, 2015, 136, 927-937.	1.0	13
92	Salpingectomy as a Means to Reduce Ovarian Cancer Risk. Cancer Prevention Research, 2015, 8, 342-348.	0.7	54
93	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	3.2	138
94	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 2015, 17, 485-492.	1.1	79
95	Correlation of DNA methylation levels in blood and saliva DNA in young girls of the LEGACY Girls study. Epigenetics, 2014, 9, 929-933.	1.3	32
96	Human Subjects Protection: An Event Monitoring Committee for Research Studies of Girls From Breast Cancer Families. Journal of Adolescent Health, 2014, 55, 352-357.	1.2	5
97	Identifying a Highly-Aggressive DCIS Subgroup by Studying Intra-Individual DCIS Heterogeneity among Invasive Breast Cancer Patients. PLoS ONE, 2014, 9, e100488.	1.1	21
98	Development of a Communication Protocol for Telephone Disclosure of Genetic Test Results for Cancer Predisposition. JMIR Research Protocols, 2014, 3, e49.	0.5	26
99	Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results. Patient Education and Counseling, 2013, 93, 413-419.	1.0	26
100	Delivery of Internet-based cancer genetic counselling services to patients' homes: a feasibility study. Journal of Telemedicine and Telecare, 2011, 17, 36-40.	1.4	47
101	Women's thoughts on receiving and sharing genetic information: Considerations for genetic counseling. Journal of Genetic Counseling, 0, , .	0.9	1